Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yuting Fang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2819-7664; OpenAlex author ID A5069874827. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12876-025-03867-2↗
  2. Recent advances in targeted therapy for pancreatic adenocarcinoma. Co-author DOI 10.4251/wjgo.v15.i4.571↗
  3. Prognostic values of abdominal body compositions on survival in advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000010988↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongkun Sun · 2 shared papers, 2023–2025 · strength 0.55
  2. Wenjie Liu · 1 shared paper, 2025 · strength 0.28
  3. Wenwei Yang · 1 shared paper, 2023 · strength 0.26
  4. Xiaojie Bian · 1 shared paper, 2018 · strength 0.09
  5. Wei Li · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.